Intraoral Photobiomodulation Therapy, Mucosal Ulcer, Myeloablative Allogeneic Hematopoietic Cell Transplantation, Oral Mucositis
Conditions
Keywords
Myeloablative Allogeneic Hematopoietic Cell Transplantation (HCT), Intraoral Photobiomodulation Therapy, Oral Mucositis, Mucosal Ulcer
Brief summary
This is a single center pilot study evaluating intraoral photobiomodulation for the prevention of oral mucositis in patients undergoing myeloablative allogeneic hematopoietic cell transplantation (alloHCT). Patients who are planned for alloHCT will receive daily intraoral photobiomodulation therapy (PBMT) using a novel LED device. The name of the study device involved in this study is: \- THOR LX2.3 with LED Lollipop
Detailed description
As part of a transplant procedure patients will receive chemotherapy in a conditioning regimen in preparation of alloHCT as well as immunosuppressive medications to help prevent graft-versus-host disease (GVHD prophylaxis). Together, these treatments will put patients at risk for developing side effects. A common side effect is oral mucositis (OM), in which mouth sores develop making eating and speaking difficult and painful. Photobiomodulation therapy (PBMT) is a light-based therapy that reduces inflammation and enhances wound healing. PBMT delivered inside the mouth has been shown to reduce OM in patients undergoing alloHCT. The name of the study device involved in this study is: \- THOR LX2.3 with LED Lollipop This research study is a Pilot Study, which is the first time that investigators are examining this LED based intraoral PBMT. The U.S. Food and Drug Administration (FDA) has not approved PBMT for this specific disease but it has been approved for other uses. The research study procedures include: screening for eligibility and study treatment including daily PBMT and clinical evaluations. Participants will receive study treatment daily from the start of conditioning chemotherapy to day +20, or discharge (if you are able to be discharged from the hospital prior to day +20), whichever occurs first. It is expected that about 20 people will take part in this research study
Interventions
DEVICETHOR LX2.3 with LED Lollipop
The intraoral PBMT device will be placed inside of the mouth to deliver the therapeutic light. Each treatment is approximately 2-3 minutes in duration. PBMT will be administered daily starting from the start of conditioning through day +20, or discharge if prior to day +20, with 27 consecutive days defined as a maximum PBMT treatment duration
Sponsors
THOR Photomedicine Ltd
Dana-Farber Cancer Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Planned to undergo myeloablative allogeneic HCT using FluBu4 conditioning and Tac-Mtx GVHD prophylaxis. * Age ≥18 years. * Ability to understand and the willingness to sign a written informed consent document.
Exclusion criteria
* Participants who have had treatment with intraoral PBMT within four weeks of admission for HSCT. * Participants who have a history of radiation therapy to the head and neck. * Participants who have a history of photosensitivity or underlying disease with known photosensitivity. * Participants who are planned to receive palifermin for OM prevention.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Duration of severe Oral Mucositis | 20 Days | Defined as the total number of days between day 0 and day +20 on which severe (WHO grade 3 or 4) OM was reported |
Countries
United States
Contacts
Primary ContactKentaro Ikeda, DDS,MPH
Outcome results
None listed